miR-551b is Associated with the Poor Prognosis and Malignant Development of Papillary Thyroid Cancer Through Regulating ERBB4

Abstract

The function of miR-551b has been widely reported in various human cancers, and its dysregulation in papillary thyroid cancer (PTC) has also been disclosed, implying its potential regulator role in PTC. The aim of the study was to evaluate the function of miR-551b in PTC development and its potential mechanism. miR-551b was evaluated in PTC tissues and cells by RT-qPCR and associated with the clinicopathological features of patients. The biological effect of miR-551b on cellular processes of PTC was assessed with the CCK8 proliferation assay and the Transwell migration and invasion assay. The potential molecular mechanism was estimated with the dual-luciferase reporter assay. miR-551b was significantly upregulated in PTC, which showed a close relationship with the malignancy and development of PTC patients. miR-551b served as a prognostic biomarker negatively related to patients’ survival together with the TNM stage. The overexpression of miR-551b exerted promoted effect on the development-related cellular processes of PTC, which was reversed by the overexpression of ERBB4. In conclusion, miR-551b could predict the poor prognosis of PTC patients and serve as a tumor promoter via suppressing ERBB4.

Key words

papillary thyroid cancer - miR-551b - ERBB4 - clinical prognosis - tumor progression - cellular processes

Publication History

Received: 08 December 2021

Accepted after revision: 04 January 2022

Article published online:
07 February 2022

• References

• 1 Seib CD, Sosa JA. Evolving understanding of the epidemiology of thyroid cancer. Endocrinol Metab Clin North Am 2019; 48: 23-35
• 2 Asa SL. The current histologic classification of thyroid cancer. Endocrinol Metab Clin North Am 2019; 48: 1-22
• 3 Raue F, Frank-Raue K. Thyroid cancer: risk-stratified management and individualized therapy. Clin Cancer Res 2016; 22: 5012-5021
• 4 Ancker OV, Kruger M, Wehland M. et al. Multikinase inhibitor treatment in thyroid cancer. Int J Mol Sci 2019; 21: 10
• 5 Zhao H, Huang T, Li H. Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer. Surgery 2019; 166: 55-60
• 6 Chen L, Heikkinen L, Wang C. et al. Trends in the development of miRNA bioinformatics tools. Brief Bioinform 2019; 20: 1836-1852
• 7 Mishra S, Yadav T, Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol 2016; 98: 12-23
• 8 Chen L, Wang X, Ji C. et al. MiR-506-3p suppresses papillary thyroid cancer cells tumorigenesis by targeting YAP1. Pathol Res Pract 2020; 216: 153231
• 9 Wang D, Guo C, Kong T. et al. Serum miR-22 may be a biomarker for papillary thyroid cancer. Oncol Lett 2019; 17: 3355-3361
• 10 Wu L, Pei F, Men X. et al. miR-329 inhibits papillary thyroid cancer progression via direct targeting WNT1. Oncol Lett 2018; 16: 3561-3568
• 11 Chang W, Wang Y, Li W. et al. Long non-coding RNA myocardial infarction associated transcript promotes the proliferation of cholangiocarcinoma cells by targeting miR-551b-3p/CCND1 axis. Clin Exp Pharmacol Physiol 2020; 47: 1067-1075
• 12 Song G, Zhang H, Chen C. et al. miR-551b regulates epithelial-mesenchymal transition and metastasis of gastric cancer by inhibiting ERBB4 expression. Oncotarget 2017; 8: 45725-45735
• 13 Sun HY, Qu ZC, Liu DM. et al. Decreased expression of miR-551b predicts poor prognosis and promotes tumorigenesis by targeting PTP4A3 in human colorectal cancer. Eur Rev Med Pharmacol Sci 2019; 23: 5741-5751
• 14 Pu M, Chen J, Tao Z. et al. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci 2019; 76: 441-451
• 15 Segers VFM, Dugaucquier L, Feyen E. et al. The role of ErbB4 in cancer. Cell Oncol (Dordr) 2020; 43: 335-352
• 16 Williams CS, Bernard JK, Demory Beckler M. et al. ERBB4 is over-expressed in human colon cancer and enhances cellular transformation. Carcinogenesis 2015; 36: 710-718
• 17 Xu J, Gong L, Qian Z. et al. ERBB4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway. Oncol Rep 2018; 39: 2892-2898
• 18 Liu Y, Song L, Ni H. et al. ERBB4 acts as a suppressor in the development of hepatocellular carcinoma. Carcinogenesis 2017; 38: 465-473
• 19 Nie FR, Li QX, Wei HF. et al. miR-326 inhibits the progression of papillary thyroid carcinoma by targeting MAPK1 and ERBB4. Neoplasma 2020; 67: 604-613
• 20 Niu Z, Zheng H, Li Z. et al. Downregulation of microRNA-551b correlates with dissemination of human oral squamous cell carcinoma. J Oral Maxillofac Surg 2020; 78: 1538-1545
• 21 Wang Y, Fan X, Xu F. et al. Expression of miR-551b and its effect on apoptosis in human gastric carcinoma. Int J Clin Exp Pathol 2018; 11: 2912-2919
• 22 Wei Z, Liu Y, Wang Y. et al. Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer. Med Oncol 2016; 33: 126
• 23 Sundvall M, Iljin K, Kilpinen S. et al. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13: 259-268
• 24 Lau C, Killian KJ, Samuels Y. et al. ERBB4 mutation analysis: emerging molecular target for melanoma treatment. Methods Mol Biol 2014; 1102: 461-480
• 25 Liu S, Gong Y, Xu XD. et al. MicroRNA-936/ERBB4/Akt axis exhibits anticancer properties of gastric cancer through inhibition of cell proliferation, migration, and invasion. Kaohsiung J Med Sci 2021; 37: 111-120
• 26 Liang H, Liu M, Yan X. et al. miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4. J Biol Chem 2015; 290: 926-940
• 27 Wei P, Li L, Zhang Z. et al. A genetic variant of miR-335 binding site in the ERBB4 3'-UTR is associated with prognosis of ovary cancer. J Cell Biochem 2018; 119: 5135-5142